In Silico Analysis of Cucurbitacin IIa and Cucurbitacin IIb as Potential Modulators of Oxidative Stress Regulatory Proteins

Sarmoko Sarmoko, Nisa Yulianti Suprahman, Refsya Azanti Putri, Ahmad Zammi Autadan Hakim, Dzaky Raihan Cahyadi, Muhammad Yogi Saputra

Abstract


Oxidative stress, resulting from imbalance between rective oxygen species (ROS) production and antioxidant defenses, contributes significantly to numerous pathological conditions, including inflammation, cancer and neurodegeneration. Natural compounds with antioxidant properties offer promising therapeutic potential. This study aims to investigate the potential of Cucurbitacin IIa and IIb to modulate oxidative stress regulatory proteins (NOS2, Lipoxygenase, KEAP1, and Xanthine oxidase) using molecular docking approaches. Target protein structures were retrieved from the RSCB Protein Data Bank. Ligand geometries were constructed and optimized using density functional theory. Molecular docking was performed using AutoDock 1.5.6 with a validated docking protocol (RPMS<2Å). Our results demonstrated favorable binding energies for both compounds with NOS2 (-9.75 and -9.57 kcal/mol) and KEAP1 (-8.52 and -9.34 kcal/mol), approaching the affinities of their respective native ligands. Moderate binding was observed with Lipoxygenase (-6.14 and -5.54 kcal/mol), while both compounds showed incompatibility with Xanthine oxidase, as evidenced by highly positive binding energies. The interaction between Cucurbitacins with NOS2, KEAP1 and Lipoxygenase was mediated through hydrogen and hydrophobic interaction. These findings provide mechanistic insight into their bioactivity and support further experimental studies for therapeutic development in oxidative stress-related disorders.

Keywords: Cucurbitacin, Molecular docking, Oxidative stress, NOS2, KEAP1.


Full Text:

PDF

References


Agu, P.C., Afiukwa, C.A., Orji, O.U., Ezeh, E.M., Ofoke, I.H., Ogbu, C.O., et al., 2023, Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management, Scientific Reports, 13, 13398. CrossRef

Aziz, N., and Jamil, R.T., 2023, Biochemistry, Xanthine Oxidase, StatPearls, Retrieved from https:// www.ncbi.nlm.nih.gov/books/NBK545245/.

Cao, H., Pauff, J.M., and Hille, R., 2014, X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin, Journal of Natural Products, 77(7), 1693–1699. CrossRef

Cubberley, R.R., Alderton, W.K., Boyhan, A., Charles, I.G., Lowe, P.N., and Old, R.W., 1997, Cysteine-200 of human inducible nitric oxide synthase is essential for dimerization of haem domains and for binding of haem, nitroarginine and tetrahydrobiopterin, The Biochemical Journal, 323(1), 141–146. CrossRef

Dai, S., Wang, C., Zhao, X.T., Ma, C., Fu, K., Liu, Y., et al., 2023, Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics, Pharmacological Research, 187, 106587. CrossRef

Fischmann, T.O., Hruza, A., Niu, X.D., Fossetta, J.D., Lunn, C.A., Dolphin, E., et al., 1999, Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation, Nature Structural Biology, 6, 233–242. CrossRef

Georgakopoulos, N., Talapatra, S., Dikovskaya, D., Naidu, S.D., Higgins, M., Gatliff, J., et al., 2022, Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode, Journal of Medicinal Chemistry, 65(10), 7380–7398. CrossRef

Gilbert, N.C., Gerstmeier, J., Schexnaydre, E.E., Börner, F., Garscha, U., Neau, D.B., et al., 2020, Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products, Nature Chemical Biology, 16, 783–790. CrossRef

Król, M., and Kepinska, M., 2020, Human Nitric Oxide Synthase—Its Functions, Polymorphisms, and Inhibitors in the Context of Inflammation, Diabetes and Cardiovascular Diseases, International Journal of Molecular Sciences, 22(1), 56. CrossRef

Kung, S.P., Umbreen, H., Wang, J.H., Tsia, C.M., Lin, T.C.C., and Chen, Y.T., 2025, Cucurbitacin B inhibits Th17 cell differentiation via the suppression of the JAK/STAT pathway and alleviates collagen-induced arthritis in mice, International Journal of Immunopathology and Pharmacology, 39, 1-17. CrossRef

Kusagawa, E., Okuda, C., Yamaguchi, R., Nakano, K., Miyake, Y., and Kataoka, T., 2022, Cucurbitacin B Down-Regulates TNF Receptor 1 Expression and Inhibits the TNF-α-Dependent Nuclear Factor κB Signaling Pathway in Human Lung Adenocarcinoma A549 Cells, International Journal of Molecular Sciences, 23(13), 7130. CrossRef

Li, Q.Z., Chen, Y.Y., Liu, Q.P., Feng, Z.H., Zhang, L., and Zhang, H., 2024, Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest, Phytomedicine, 126, 155177. CrossRef

Li, Y., Li, Y., Yao, Y., Li, H., Gao, C., Sun, C., and Zhuang, J., 2023, Potential of cucurbitacin as an anticancer drug, Biomedicine & Pharmacotherapy, 168, 115707. CrossRef

Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., Della-Morte, D., et al., 2018, Oxidative stress, aging, and diseases, Clinical Interventions in Aging, 2018(13), 757-772. CrossRef

Liu, Z., Gao, M., Yan, F., Zhang, H., Wang, L., Zhao, Y., et al., 2025, Cucurbitacin IIb mitigates concanavalin A-induced acute liver injury by suppressing M1 macrophage polarization, International Immunopharmacology, 147, 113964. CrossRef

Ma, F., Chen, Y., Ni, Y., He, H., Ji, O., Quan, X., and Qi, B., 2025, Allosteric inhibitors for the treatment of cancers (2021-): A review from medicinal chemistry perspectives, Journal of Molecular Structure, 1344, 142985. CrossRef

Mashima, R., and Okuyama, T., 2015, The role of lipoxygenases in pathophysiology; new insights and future perspectives, Redox Biology, 6, 297– 310. CrossRef

National Center for Biotechnology, 2025, PubChem Compound Summary for CID 181183, Hemslecin A, Retrieved July 23, 2025, from https://pubchem.ncbi.nlm.nih.gov/compound/Hemslecin-A.

National Center for Biotechnology Information, 2025, PubChem Compound Summary for CID 72421, cucurbitacin IIb, Retrieved July 23, 2025, from https://pubchem.ncbi.nlm.nih.gov/ compound/cucurbitacin-IIb.

Newman, D.J., and Cragg, G.M., 2020, Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019, Journal of Natural Products, 83(3), 770–803. CrossRef

Peng, Y., Chen, T., Luo, L., Li, L., Cao, W., Xu, X., et al., 2020, Isoforskolin and Cucurbitacin IIa promote the expression of anti-inflammatory regulatory factor SIGIRR in human macrophages stimulated with Borrelia burgdorferi basic membrane protein A, International Immunopharmacology, 88, 106914. CrossRef

Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., et al., 2017, Oxidative Stress: Harms and Benefits for Human Health, Oxidative Medicine and Cellular Longevity, 2017, 8416763. CrossRef

Sies, H., Berndt, C., and Jones, D.P., 2017, Oxidative Stress, Annual Review of Biochemistry, 86, 715–748. CrossRef

Suzuki, T., and Yamamoto, M., 2015, Molecular basis of the Keap1-Nrf2 system, Free Radical Biology & Medicine, 88(Part B), 93–100. CrossRef

Torres-Moreno, H., Marcotullio, M.C., Velazquez, C., Arenas-Luna, V.M., Hernández-Gutiérrez, S., and Robles-Zepeda, R.E., 2020, Cucurbitacin IIb from Ibervillea sonorae Induces Apoptosis and Cell Cycle Arrest via STAT3 Inhibition, Anti-Cancer Agents in Medicinal Chemistry, 20(10), 1188–1196. CrossRef

Yu, K., Yang, X., Li, Y., Cui, X., Liu, B., and Yao, Q., 2020, Synthesis of cucurbitacin IIa derivatives with apoptosis-inducing capabilities in human cancer cells, RSC Advances, 10(7), 3872–3881. CrossRef

Zeng, Y., Wang, J., Huang, Q., Ren, Y., Li, T., Zhang, X., et al., 2021, Cucurbitacin IIa: A review of phytochemistry and pharmacologym, Phytotherapy Research, 35(8), 4155–4170. CrossRef

Zhao, Y., Jiang, B., and Zuo, S., 2025, Cucurbitacin IIa Alleviates Colitis via Promoting the Release of Host-Derived Extracellular Vesicles Encapsulating microRNA-30b-5p, Journal of Inflammation Research, 18, 1447–1458. CrossRef

Zieniuk, B., and Pawełkowicz, M., 2023, Recent Advances in the Application of Cucurbitacins as Anticancer Agents, Metabolites, 13(10), 1081. CrossRef




DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev15iss3pp224-236

Copyright (c) 2024 Indonesian Journal of Cancer Chemoprevention

Indexed by:

                  

               

 

Indonesian Society for Cancer Chemoprevention